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Abstract
XIAP up-regulation is associated with chemotherapy resistance. Phenoxodiol causes XIAP
degradation and chemotherapy sensitization in ovarian cancer. Here we assessed XIAP expression
in melanomas, using tissue microarrays containing 436 melanomas and 336 nevi by a novel method
of automated, quantitative analysis (AQUA). We used S100 to define pixels as melanoma (tumor
mask) within the array spot, and measured XIAP expression using Cy5-conjugated antibodies
within the mask. XIAP expression was significantly higher in melanomas than nevi (P < 0.0001), and
higher in metastatic than primary lesions (P < 0.0001). We then assessed a panel of melanoma cell
lines for XIAP expression, and found high expression in all cell lines. Three of the cell lines were
assessed for Phenoxodiol and Carboplatin sensitivity; all were resistant to Carboplatin and showed
variable sensitivity to Phenoxodiol. Pre-treating Phenoxodiol sensitive cells with Phenoxodiol prior
to Carboplatin resulted in XIAP degradation, associated with Carboplatin sensitization and
apoptosis, whereas exposing Phenoxodiol resistant cells to Phenoxodiol resulted in less XIAP
degradation and minimal Carboplatin sensitization. We conclude that XIAP levels in clinical
specimens are significantly higher in melanomas than their benign counterparts, and higher in
metastatic than in primary specimens, suggesting an association with malignant progression and
disease aggression. Melanoma resistance to Carboplatin is possibly due to XIAP over-expression.
Phenoxodiol can sensitize melanoma cells to Carboplatin in vitro with corresponding XIAP
degradation, although the precise target and mechanism of action of Phenoxodiol are subject to
further assessment. Targeting XIAP warrants additional investigation as a therapeutic approach for
metastatic melanoma.
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Background
The incidence of cutaneous melanoma in the United
States is rising faster than that of any other malignancy,
with 62,190 expected new cases diagnosed in 2006 [1,2].
This increase in incidence, compounded by the lack of
effective therapy once the disease has metastasized, under-
scores the need for improved methods of treating patients
with unresectable melanoma. Melanoma is usually resist-
ant to standard chemotherapy and radiation therapy. A
number of chemotherapeutic and biological agents have
activity in metastatic melanoma, albeit with disappoint-
ingly low response rates of less than 25% for any single
agent or combination of agents, and none has improved
overall survival when compared with observation [3-5].
Single agent dacarbazine remains one of the standard
treatments, although the control arm of a recent clinical
trial demonstrated a dismal response rate of only 6.8% to
dacarbazine [6]. Single agent platinum and taxane drugs
are viable alternatives, yielding comparable response rates
of 3–20% [7,8]. Our understanding of mechanisms of
resistance to chemotherapy is limited, as is our ability to
overcome resistance, and new, well tolerated agents and
approaches are required to sensitize melanoma cells to
chemotherapy in order to improve outcome.
One of the most important mechanisms by which anti-
cancer chemotherapy induces cell death is by activating
the apoptotic cascade [9,10]. There are two chief apoptotic
pathways, the death receptor pathway (the direct path-
way) and the mitochondrial pathway (the indirect path-
way). These pathways are described in detail in the
literature [11]. The two pathways are inhibited by a group
of proteins called the IAP (inhibitors of apoptosis) pro-
teins, of which the X-linked inhibitor of apoptosis protein
(XIAP) is a key member. XIAP (also known as hILP, MIHA
and BIRC4) selectively binds and inhibits caspases -3, -7
and inhibits Apaf-1-cytochrome c-mediated actvitaion of
caspase-9, but does not inhibit caspase-8, and thus is
responsible for inhibiting much of the apoptotic path-
ways [12-14]. As opposed to other members of the IAP
family, XIAP is the only member capable of direct inhibi-
tion of both the execution and initiation phases of the
apoptotic cascade; it inhibits apoptotic activation by
inhibiting caspase-9, and inhibits the execution phase by
inhibiting the effector caspases, caspase-3 and caspase-7
[15]. The IAP proteins promote ubiquitination and pro-
teasomal degradation of the caspases to which they bind
via their RING-finger motif, which enables them to serve
as E3 ubiquitin ligases [16]. XIAP has been shown in other
cancers to be associated with resistance to chemotherapy
[17-19], as well as resistance to radiation therapy [20,21].
Thus, targeting XIAP is likely to be a useful approach to
overcoming resistance to chemotherapy. A number of pre-
clinical studies have demonstrated efficacy of XIAP inhib-
itors for a variety of tumors [13,22,23]. Down-regulation
of XIAP in melanoma cells by siRNAs sensitizes these cells
to TRAIL-induced apoptosis [24].
Increased expression of XIAP has been shown to be asso-
ciated with aggressive malignant behavior and disease
progression in a number of malignancies, including lym-
phoma, breast cancer, lung cancer and renal cell carci-
noma [18,25-27]. Zhang et al demonstrated up-regulation
of XIAP in a limited number of melanoma cell lines [28],
and Bowen et al demonstrated higher expression of XIAP
in 4 melanoma cell lines than in normal melanocytes, and
found an association between XIAP expression and resist-
ance to chemotherapy and radiation therapy [29]. How-
ever, to the best of our knowledge, there are no large
cohort studies that thoroughly assess expression levels of
XIAP in specimens from patients with melanoma.
In previous studies we assessed the activity of Phenoxo-
diol, a novel isoflavone derivative, in ovarian cancer [30].
We showed that Phenoxodiol has activity as a single agent
in patient-derived, chemotherapy-resistant ovarian cancer
cell lines, via induction of Fas-mediated apoptosis. This
effect is dependent upon the activation of the caspase sys-
tem and inhibiting XIAP [30]. Subsequent studies showed
that pretreatment of cells with Phenoxodiol prior to treat-
ment with Docetaxel results in sensitization to Docetaxel,
which is mediated by XIAP [17]. We showed that inhibi-
tion of XIAP by RNA interference yields sensitization to
Docetaxel similar to that seen with Phenoxodiol [17]. Fur-
thermore, we showed that pretreatment of chemotherapy-
resistant ovarian cancer cells with Phenoxodiol results in
decreases in XIAP levels and sensitization to Gemcitabine,
Carboplatin and Paclitaxel [19]. Although the precise tar-
get of Phenoxodiol remains unknown, it inhibits XIAP by
causing early, caspase independent self-ubiquitination
and degradation of XIAP by the proteasome [19]. In these
studies we showed that when cells are transfected with a
phospho-mimic form of XIAP, which is resistant to pro-
teasomal degradation, Phenoxodiol activity is inhibited,
indicating that XIAP degradation is a critical component
of Phenoxodiol-induced apoptosis.
Phenoxodiol has been assessed in Phase I and II studies,
and is very well tolerated in both the oral and the intrave-
nous forms [19,31]. The toxicities are limited to mild
depression, lightheadedness, thrombocytopenia, hyper-
tension and headache. Responses have been documented
in platinum-resistant ovarian cancer, both as a single
agent and when used in combination with platinum
drugs [32].
Given that most melanoma patients do not respond to
platinum-based therapy, we assessed the activity of Phe-
noxodiol in Carboplatin-resistant, early passage
melanoma cell lines. We hypothesize that resistance ofJournal of Translational Medicine 2007, 5:6 http://www.translational-medicine.com/content/5/1/6
Page 3 of 15
(page number not for citation purposes)
melanoma cells to chemotherapy is associated with high
baseline expression of XIAP. We further hypothesize that
drugs that (directly or indirectly) cause XIAP degradation
can result in sensitization of melanoma cells to chemo-
therapy.
The purpose of the present work was to assess the expres-
sion patterns of XIAP in a large cohort of melanoma
tumors and benign nevi, and to assess the association of
expression with disease stage. In order to obtain quantita-
tive, objective measures of expression, we used our newly
developed method of automated, quantitative analysis
(AQUA™) of tissue microarrays. This method has been
validated, has proven to be more accurate than patholo-
gist-based scoring of brown stain [33,34], and has been
used in a number of prior melanoma studies [35-38].
AQUA provides continuous output scores that correspond
to in situ XIAP levels in the melanocytes. We found signif-
icantly higher expression levels of XIAP in melanomas
than in benign nevi. We also found global high expression
in a panel of melanoma cell lines. We subsequently
assessed the sensitivity of melanoma cell lines to Carbopl-
atin, and found that all three cell lines studied were resist-
ant to the drug. We assessed our ability to sensitize these
cells to Carboplatin by pretreatment with Phenoxodiol,
and the association with XIAP levels and XIAP cleavage.
Materials and methods
Tissue Microarray Construction
The melanoma tissue microarrays were constructed as pre-
viously described [35]. A total of 232 primary melanomas,
15 local recurrences and 299 metastatic cores, each meas-
uring 0.6 mm in diameter, were spaced 0.8 mm apart on
a glass slides. The cohort was constructed from paraffin-
embedded, formalin-fixed tissue blocks obtained from
the Yale University Department of Pathology Archives.
Specimens and clinical information were collected under
the guidelines and approval of a Yale University Institu-
tional Review Board. The cohort has been used in prior
publications [39-41]. The specimens were resected
between 1959 and 2000, with a follow-up range between
2 months and 40 years, and a mean follow-up time of 6.7
years. Age at diagnosis ranged from 18 to 91 years (mean
age 52.4 years). The cohort included 55% males and 45%
females. The time between tumor resection and tissue fix-
ation was not available. A pathologist reviewed slides
from all of the blocks to select representative areas of inva-
sive tumor to be cored. The cores were placed in the tissue
microarray block using a Tissue Microarrayer (Beecher
Instruments, Silver Spring, MD). The tissue microarrays
were then cut into 0.5 µm sections and placed on glass
slides using an adhesive tape-transfer system (Instrumed-
ics, Inc., Hackensack, NJ) with UV cross-linking. Similarly,
a tissue microarray was made containing cores from 540
benign nevi. The nevus array contained 31 metastatic
specimens from patients that were also represented on the
melanoma array. Both arrays contained identical cell
lines, cored from pellets, as previously described [42]. The
overlapping metastatic specimens and cell lines were used
for normalization of the scores obtained from the benign
and malignant arrays.
Immunohistochemistry
Staining was performed for automated analysis of
melanoma specimens as previously described. Briefly,
slides were deparaffinized in xylene, and transferred
though two changes of 100% ethanol. For antigen
retrieval, the slides were boiled in a pressure cooker con-
taining 6.5 mM sodium citrate (pH 6.0). Endogenous per-
oxidase activity was blocked in a mixture of methanol and
2.5% hydrogen peroxide for thirty minutes at room tem-
perature. To reduce non-specific background staining,
slides were incubated at room temperature for 30 minutes
in 0.3% bovine serum albumin/1× Tris-buffered saline.
Slides were incubated at 4°C overnight in a humidity tray
with a primary mouse anti-human XIAP antibody (BD
Transduction Laboratories) at a dilution of 1:50. To create
a tumor mask, slides were simultaneously incubated over-
night with a primary rabbit anti-human S100 antibody
diluted at 1:500. Slides were rinsed three times in 1× Tris-
buffered saline/0.05% Tween-20 and incubated for 1
hour at room temperature with goat anti-mouse HRP to
identify the target and goat anti-rabbit IgG conjugated to
Alexa 546 to identify the S100 mask. The slides were
washed again as above and incubated for ten minutes
with Cy5 directly conjugated to tyramide (Perkin Elmer,
Boston, MA) at a dilution of 1:50 for primary antibody
identification. The slides were rinsed again and cover-slips
were mounted with ProLong Gold antifade reagent, which
contained 4,6-diamidine-2-phenylindole (DAPI) to iden-
tify the nuclei.
Automated Image Acquisition
Images were acquired using our automated method, as
described previously [33]. Briefly, areas of tumor were dis-
tinguished from stroma by creating a mask with the S100
signal tagged with Alexa 546. Coalescence of S100 at the
cell surface was used to identify the membrane/cytoplasm
compartment within the tumor mask, while 4,6-diamid-
ino-2-phenylindole (DAPI) was used to identify the
nuclear compartment within the tumor mask. The target
marker, XIAP, was visualized with Cy5 (red). Cy5 was
used because its emission peak is outside the color spec-
trum of tissue autoflourescence. Multiple monochro-
matic, high resolution (1024 × 1024 pixel 0.5-µm)
grayscale images were obtained for each histospot, using
the 10× objective of an Olympus AX-51 epifluorescence
microscope (Olympus, Melville, NY) with an automated
microscope stage. Digital image acquisition was driven byJournal of Translational Medicine 2007, 5:6 http://www.translational-medicine.com/content/5/1/6
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custom program and macro-based interfaces with IPLabs
software (Scanalytics Inc., Fairfax, VA).
Algorithmic Image Analysis
Images were analyzed using algorithms that have been
previously extensively described [33]. Two images (one
in-focus and one out-of-focus) were taken of the compart-
ment specific tags and the target marker. A percentage of
the out-of-focus image was subtracted from the in-focus
image for each pixel, representing the signal to noise ratio
of the image. An algorithm described as RESA (Rapid
Exponential Subtraction Algorithm) was used to subtract
the out-of-focus information in a uniform fashion for the
entire microarray. Subsequently, the PLACE algorithm
(Pixel Locale Assignment for Compartmentalization of
Expression) was used to assign each pixel in the image to
a specific subcellular compartment and the signal in each
location was calculated. Pixels that could not accurately
be assigned to a compartment were discarded. The data
were saved and subsequently expressed as the average sig-
nal intensity per unit of compartment area. For the
nuclear and membrane/cytoplasmic compartments, the
image was measured on a scale of 0–255, and expressed as
target signal intensity relative to the compartment area.
Statistical Analysis
The JMP5 (SAS Institute Inc., Cary, NC) software package
was used for data analyses. Continuous AQUA scores of
target expression were divided by the median score and
associations with clinical and pathological parameters
were completed using the Chi-Square test. The prognostic
significance of the parameters was assessed for predictive
value using the Cox proportional hazards model with
overall survival as an end point. Comparison of expres-
sion in malignant and benign specimens, as well as com-
parisons between primary and metastatic specimens was
performed with unpaired t-tests.
Cell Lines and Drugs
We used low passage (passage 3–18) melanoma cell lines
established from tumors excised from patients treated at
the Yale Cancer Center, obtained from the Cell Culture
Facility of the Yale Skin Disease Research Core Center
(YSDRCC). Cells were grown as previously described [43].
The melanoma cell line YUMAC was derived from an in-
transit metastasis from a male patient, YUSAC2 was from
a soft tissue metastasis from a male patient, and YUGEN8
was from a brain metastasis of a female patient. 501 mel,
624 mel and 888 mel were generously provided by Dr.
Steven A. Rosenberg, National Cancer Institute, Bethesda,
MD. The mm127 cell line was generously provided by Dr
Peter Parsons of the Queensland Institute of Medical
Research, Australia. Cells where grown in F12 medium
with 10% FBS at 37°C in 5% CO2. Phenoxodiol was gen-
erously provided by Novogen, LTD, Australia. Carbopla-
tin was purchased from Sigma Chemical Co. (St. Louis,
MO).
Cell Viability Assay
Cell viability was evaluated using the CellTiter 96 Aque-
ous One Solution Cell Proliferation Assay according to the
manufacturer's instructions (Promega, USA), as previ-
ously described [44]. Briefly 4 × 104 cells per well were
plated in triplicate in a 96-well microtiter plate (BD Bio-
sciences). Cells were grown to 60% confluency, at which
stage the medium was replaced with reduced serum phe-
nol-depleted medium, OPTI-MEM (Gibco™, Invitrogen
Corp, Grand Island, NY), and incubated for 4 hours prior
to treatment. Following treatment, 20 µL of CellTiter 96
Aqueous One Solution was added to each well, and the
plate was incubated at 37°C for 2 hours. Optical densities
were measured at 490 nm using a Titertek Multiskan
MCC/340 (Titertek Instruments Inc., Alabama). Values of
treated cells were compared to untreated cells and
reported as percent viability.
Western Blot Analysis
Cells were plated in 35 mm2 Petri dishes (BD Biosciences,
San Jose, CA) and grown to 60% confluency for treat-
ment. Following treatment, cells were lysed in Radioim-
munoprecipitation (RIPA) buffer containing the protease
inhibitor cocktail, Complete (Roche Diagnostics, Man-
nheim, Germany). Protein concentrations were calculated
by the BCA (Bicinchoninic Acid) assay (Pierce Biotechnol-
ogy, Rockford, IL). Protein (20 µg) was separated in a
sample buffer [2.5% SDS, 10% glycerol, 5% β-mercapto-
ethanol, 0.15 M Tris (pH = 6.8) and 0.01% bromophenol
blue] and subjected to SDS-polyacrylamide gel electro-
phoresis using precast 12% polyacrylamide gels (Bio-Rad
Laboratories, Hercules, CA), and transferred to pure nitro-
cellulose membranes (Bio-Rad). To inhibit non-specific
binding, membranes were blocked in 5% powdered milk
for 1 hour at room temperature. The membranes were
washed three times in PBS with 0.5% tween (PBS-T) for 10
minutes per wash and incubated with primary antibodies
diluted in PBS-T with 1% milk, in a 50 mL falcon tube on
a rotator overnight at 4C. The following primary antibod-
ies and concentrations were used: mouse anti-XIAP, (BD
Transduction Laboratories) at 1:1000, mouse anti-Cas-
pase-2 (BD Biosciences) at 1:1,000, rabbit anti-Bid (Cell
Signaling, Beverly, MA) at 1:2500, and rabbit anti-actin
(Sigma) at 1:100. Following primary incubation, mem-
branes were washed as described above and incubated
with horse anti-mouse or horse anti-rabbit peroxidase
(Vector Laboratories, Burlingame, CA), diluted 1:10,000,
for 1 hour at room temperature. Membranes were washed
again in PBS-T as above and washed three times in
ddH20, 10 minutes per wash. Finally, proteins were visu-
alized using enhanced chemiluminescence (Pierce Bio-
technology).Journal of Translational Medicine 2007, 5:6 http://www.translational-medicine.com/content/5/1/6
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Caspase -3, -8, and -9 activity
Following drug treatment of cells, 10 µg of protein in 50
µL of ddH20 was combined with equilibrated Caspase-
Glo™ 3/7, 8, or 9 reagents (Promega). After incubation for
1 hour at room temperature, luminescence was measured
using a TD 20/20 Luminometer (Turner Designs, Sunny-
vale, CA). Blank values were subtracted and fold-increase
in activity was calculated based on activity measured from
untreated cells. Each sample was measured in duplicate.
Results
XIAP expression in human tumors
To assess for intra-tumor heterogeneity of XIAP expression
in melanoma specimens, we used tissue arrays containing
tumor cores from 565 melanoma patients. Two separate
slides, each containing a core from a different area of the
tumor for each patient, were stained with a specific anti-
body for XIAP. Positive XIAP immunoreactivity was
observed predominantly in the membranous/cytoplasmic
compartment. The nuclear compartment had very low
immunoreactivity, therefore only the membranous/cyto-
plasmic compartment was analyzed. We did not see differ-
ences in staining patterns within the tumor mask within a
histospot. Using the Pearson correlation test, we found
that the scores from matching spots on the two arrays
were highly correlated (P < 0.0001) for XIAP expression.
Figure 1 shows regression plots for the two arrays assessed
for XIAP expression (R = 0.7).
AQUA scores for melanoma specimens ranged from 6.07
to 109.91, with a median score of 23.47. Examples of
strong and weak XIAP staining are shown in Figure 2. Fig-
ure 2C represents a histospot with an AQUA score of
52.91, and Figure 2D a score of 21.85.
Regression plot of XIAP staining comparing scores from two slides containing histospots taken from the same patients, from  different locations within the tumor Figure 1
Regression plot of XIAP staining comparing scores from two slides containing histospots taken from the same patients, from 
different locations within the tumor.Journal of Translational Medicine 2007, 5:6 http://www.translational-medicine.com/content/5/1/6
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Strong (A) and weak (B) XIAP expression (red) in melanoma using ×10 magnification, employing S100 (green) to define tumor  and DAPI (blue) to define nuclei Figure 2
Strong (A) and weak (B) XIAP expression (red) in melanoma using ×10 magnification, employing S100 (green) to define tumor 
and DAPI (blue) to define nuclei. Strong (C) and weak (D) XIAP expression are shown using ×60 magnification. The strong 
spot corresponds to an AQUA score of 52.91 and the weak spot to a score of 21.85.Journal of Translational Medicine 2007, 5:6 http://www.translational-medicine.com/content/5/1/6
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AQUA scores from both slides were combined to give a
single dataset. Of the 565 melanoma patients in the
cohort, 228 had cores that were interpretable on both
slides, and 283 were interpretable for one slide. Tumor
spots were deemed uninterpretable if they had insufficient
tumor cells, loss of tissue in the spot or an abundance of
necrotic tissue. For patients who had two interpretable
histo-spots, a composite score was formed by taking the
average of the two scores. For patients with only one inter-
pretable core, the single score was used. The combined
dataset had scores for 436 melanoma patients; 195 pri-
mary specimens and 241 metastatic specimens. For the
histospots on the nevus array, we obtained 336 scores.
We assessed the differences in XIAP expression between
benign and malignant tissue. Unpaired t-tests showed that
expression was significantly higher in malignant versus
benign tissue cores (P < 0.0001), as shown in Figure 3.
Moreover, the expression of XIAP was significantly higher
in metastatic specimens than in primary specimens (P <
0.0001), as shown in Figure 3. The mean AQUA scores for
XIAP were 10.4 in nevi specimens, 24 in primary lesions
and 33.7 in metastatic lesions.
AQUA gives continuous output data, as opposed to
brown stain, which is read as "positive" or "negative".
Here we define "low" or "normal" AQUA scores as those
that fall at or below the 95th percentile score for nevi. This
score was 20 for XIAP, and scores above these cutoffs in
the malignant specimens were considered "high". Table 1
demonstrates the association between high XIAP expres-
sion and commonly used clinical and pathological varia-
bles. High XIAP was associated with advanced stage
(metastatic) disease and thick lesions over 2 mm (p =
0.0003 and p = 0.0264, respectively).
XIAP expression in a panel of human cell lines
Given that chemotherapy response information was not
available on most patients in our cohort, we sought to
assess the association between high XIAP expression and
chemotherapy resistance in melanoma using cell lines.
We studied XIAP expression in a panel of melanoma cell
lines by Western blot analysis. As shown in figure 4, all the
cell lines studied expressed XIAP.
Phenoxodiol inhibition of XIAP expression in melanoma 
cells
A central effect of Phenoxodiol-induced apoptosis in dif-
ferent cell types, is degradation of XIAP [17,19]. Therefore
we evaluated the effect of Phenoxodiol on three patient-
derived melanoma cell lines. We used a concentration of
10 µg/ml, based on previous studies in ovarian cancer
[19], and cell viability was determined by the CellTiter 96®
Aqueous One Solution Cell Proliferation Assay. As shown
in Figure 5, two of the three cell lines (YUMAC and
YUGEN8) were sensitive to 10 µg/ml of Phenoxodiol,
while the third cell line (YUSAC2) was resistant. YUSAC2
cells were also resistant to Carboplatin (as detailed below)
and surprisingly showed increased cell viability in the
presence of Carboplatin compared to the control. This
phenomenon has been demonstrated in vivo by other
researchers who found that melanoma cell lines that were
resistant to dacarbazine had higher growth and metastatic
potential than untreated cells [45].
We then studied the effect of Phenoxodiol on XIAP
expression and function in one of the two Phenoxodiol
sensitive cell lines, YUMAC, and in the resistant cells
(YUSAC2). Exposure of YUMAC cells to Phenoxodiol
decreased the level of XIAP at 4 hours compared with pre-
Unpaired t-tests showing significant differences in expression  of XIAP between benign and malignant specimens (p <  0.0001), and significant differences between primary and met- astatic lesions (p < 0.0001) Figure 3
Unpaired t-tests showing significant differences in expression 
of XIAP between benign and malignant specimens (p < 
0.0001), and significant differences between primary and met-
astatic lesions (p < 0.0001).
Table 1: Association between high XIAP expression and other prognostic clinical and pathological variables.
Clinical/Pathological Variable Chi-Square Value P-value
Disease Stage (metastatic vs. primary) 13.071 0.0003
Breslow (>2 mm) 4.927 0.0264
Clark Level (IV-V) 3.559 0.1687
Age (<40 years) 0.338 0.5613
Gender (male) 1.800 0.1798
Presence of Ulceration 2.016 0.3650Journal of Translational Medicine 2007, 5:6 http://www.translational-medicine.com/content/5/1/6
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treament levels. A further decrease in XIAP levels was seen
at 8 hours post treatment and no expression was observed
at 24 hours (Figure 6A). Changes in XIAP expression cor-
responded to increases in activity of caspases -3, -8 and -9
(Figure 6A). On the other hand, with the YUSAC2 cells,
the degree XIAP degradation and resultant caspase activa-
tion was much less than what was observed with YUMAC
cells (Figure 6B).
Sensitization of melanoma cell lines to Carboplatin by 
Phenoxodiol and the association with XIAP levels
YUMAC, YUSAC2 and YUGEN8 cells were evaluated for
sensitivity to Carboplatin. The cells were treated with
increasing concentrations of Carboplatin, ranging from
50–200 µg/ml for 24 hours, and cell viability was deter-
mined by the CellTiter 96® Assay. As shown in Figure 7A,
all three cell lines were resistant to Carboplatin, with
YUSAC2 demonstrating the most resistance. As with Phe-
noxodiol, YUSAC2 cells grew more in the presence of Car-
boplatin than in medium alone. The IC50 for all three cell
lines was greater than 200 µg/ml.
In previous studies we have shown that resistance of ovar-
ian cancer cells to Carboplatin is associated with high
XIAP levels, and that this resistance can be reversed by pre-
treatment with Phenoxodiol, which causes XIAP degrada-
Expression of XIAP in melanoma cell lines Figure 4
Expression of XIAP in melanoma cell lines. XIAP expression was determined by western blot analysis in 7 melanoma cell lines, 
ordered left to right: Mel 624 AB, Mel 624 MC, Mel 501, Mel 888, YUGEN8, YUMAC, MM127.
Cell viability assays demonstrating the effect of 10 µg/ml Phenoxodiol on three melanoma cell lines, YUMAC, YUSAC2 and  YUGEN 8 Figure 5
Cell viability assays demonstrating the effect of 10 µg/ml Phenoxodiol on three melanoma cell lines, YUMAC, YUSAC2 and 
YUGEN 8. Each experiment was performed in triplicate and viability was determined by the CellTiter 96 Aqueous One Solu-
tion Cell Proliferation Assay, reported as a percentage of viable cells relative to untreated cells.Journal of Translational Medicine 2007, 5:6 http://www.translational-medicine.com/content/5/1/6
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tion and ubiquitination [19]. Here we assessed whether
pretreatment of melanoma cells with Phenoxodiol
reverses the baseline resistance to Carboplatin and
whether this reversal is associated with XIAP degradation.
Melanoma cells were pre-treated with 10 µg/ml of Phe-
noxodiol for 4 hours, Phenoxodiol was removed from the
media and the cells were treated with increasing doses of
Carboplatin (50–200 µg/ml) for an additional 24 hours.
As shown in Figure 7B, pre-treatment for only 4 hours
with Phenoxodiol sensitized the YUMAC and YUGEN8
cells to Carboplatin, as demonstrated by a decrease in the
IC50 of Carboplatin for these cell lines to < 50 µg/ml and
< 200 µg/ml, respectively. Pretreatment with Phenoxodiol
for 4 hours did not significantly reduce the resistance of
YUSAC2 to Carboplatin, with the IC50 for Carboplatin
remaining at > 200 µg/ml.
In order to study the intracellular effect of Phenoxodiol on
melanoma cells, we pretreated YUMAC cells with a
shorter exposure to Phenoxodiol (2 hours) followed by
treatment with Carboplatin. We assessed the effect on
some apoptotic mediators, including pro-caspase-2, BID
(a member of the mitochondrial pathway that is activated
after caspase-2 activation) XIAP and caspase-3/7. Treat-
ment with Carboplatin alone had no effect on XIAP levels,
or the other components of the apoptotic cascade. Treat-
ment with Phenoxodiol for 2 hours had some effect on
XIAP expression and induced caspase-2 activation. When
Carboplatin was added after Phenoxodiol pre-treatment,
remarkable XIAP degradation was observed, coupled with
caspase-2 and Bid activation (as demonstrated by disap-
pearance of the bands representing the inactive forms of
caspase-2 and Bid), and a significant increase on the activ-
ity of caspase-3/7 (Figure 8).
Discussion
The purpose of this study was to 1) assess the expression
of XIAP in a quantitative fashion on a large cohort of
melanoma specimens in an objective, automated fashion,
and to compare expression of XIAP in malignant speci-
mens to benign nevi and 2) assess the association between
XIAP expression and resistance to Carboplatin, and the
effect of Phenoxodiol on XIAP. In our large cohort of
melanomas and nevi we show significantly higher expres-
sion in tumors than in nevi, and XIAP expression was sig-
nificantly higher in metastatic specimens than in primary
melanomas. Among primary tumors we found an associ-
ation between high XIAP expression and deep lesions (>2
mm). Furthermore, we demonstrate that degradation of
XIAP by Phenoxodiol confers Carboplatin sensitization in
melanoma cells.
One of the major problems in the treatment of unresecta-
ble melanoma is the inherent resistance to chemotherapy;
response rates to any single chemotherapeutic agent or
combination of agents are in the order of 25% at best, and
the responses are typically not durable [46]. Chemother-
apy resistance in melanoma cells is multifactorial. Mecha-
nisms implicated in chemoresistance in melanoma
include (but are not limited to) multi-drug resistance
Effect of Phenoxodiol on YUMAC (A) and YUSAC2 (B) cells Figure 6
Effect of Phenoxodiol on YUMAC (A) and YUSAC2 (B) cells. Cells were treated with a single dose of Phenoxodiol (10 µg/mL) 
for varying time points (0, 4, 8, and 24 hours). XIAP and caspase-2 expression were determined by western blot analysis. Cas-
pase-3, -8, and -9 activities were determined by the Caspase-Glo 3, 8, and 9 assays, respectively.Journal of Translational Medicine 2007, 5:6 http://www.translational-medicine.com/content/5/1/6
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Cell viability assays demonstrating the effect of Phenoxodiol on melanoma cells Figure 7
Cell viability assays demonstrating the effect of Phenoxodiol on melanoma cells. (A) Cells were treated with increasing concen-
trations of Carboplatin (50–200 µg/mL) alone or (B) cells were pretreated with 10 µg/mL Phenoxodiol for 4 hours followed by 
treatment with increasing concentrations of Carboplatin. Each experiment was performed in triplicate and viability was deter-
mined by the CellTiter 96 Aqueous One Solution Cell Proliferation Assay, reported as a percentage of viable cells relative to 
untreated cells.Journal of Translational Medicine 2007, 5:6 http://www.translational-medicine.com/content/5/1/6
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Effect of pretreatment with Phenoxodiol on the apoptotic cascade Figure 8
Effect of pretreatment with Phenoxodiol on the apoptotic cascade. YUMAC cells received either no treatment, 200 µg/mL of 
Carboplatin for 24 hours, 10 µg/mL of Phenoxodiol for 2 hours, or 10 µg/mL of Phenoxodiol for 2 hours followed by 200 µg/
mL Carboplatin for 24 hours. Both pro- and antiapoptotic protein expression was determined by Western blot analysis. Activ-
ity of caspase-3 was determined using the Caspase-Glo 3\7 assay.
Figure 8Journal of Translational Medicine 2007, 5:6 http://www.translational-medicine.com/content/5/1/6
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transporter proteins [47,48], oxidative agents such as
nitric oxide [49], DNA repair pathways [50] and intrinsic
resistance to apoptosis, as reviewed by Soengas et al [51].
Chemotherapy resistance associated with defects in the
apoptotic cascade is due to the over-expression of factors
that inhibit the apoptotic signal initiated by cytotoxic
agents. XIAP is one of the major inhibitors of apoptosis,
due to its ability to block both the intrinsic and extrinsic
pathways. We did not have information on chemotherapy
treatment and response to therapy on the patients
included in this cohort. We are currently collecting speci-
mens from a randomized clinical trial in which metastatic
melanoma patients on the control arm are being treated
with chemotherapy alone, and we will assess XIAP levels
and the association with chemotherapy response.
A number of drugs that directly target XIAP are in develop-
ment, including antisense oligonucleotide molecules
(AEG 35156, Aegra pharmaceuticals, Montreal, Canada)
and small molecule inhibitors, as reviewed by Schimmer
et al [15], and these inhibitors might enhance chemosen-
sitivity in XIAP over-expressing tumors. Finding signifi-
cantly higher expression in melanoma than in nevi was
encouraging for development of XIAP-targeting therapies
in melanoma. However, there was some overlap in the
range of expression between benign nevi and melanoma
specimens, particularly for primary melanomas. It is
unclear why some nevi had relatively high XIAP levels;
although these nevi were not thought to be "atypical" on
pathologic evaluation, some benign melanocytes might
be undergoing early malignant transformation. Given that
these benign nevi were excised, we cannot assess the asso-
ciation between XIAP expression and clinical outcome in
nevi. Moreover, other researchers have shown that
somatic mutations are already evident in nevi, but not in
normal skin, such as the presence of activating B-raf and
N-ras mutations [52,53]. Because level of expression may
be an important determinant of sensitivity to XIAP tar-
geted therapies, we sought to determine the percent of
samples that displayed XIAP over-expression as compared
to nevi. For this purpose, we defined high expression as
exceeding the AQUA score in 95% of benign nevi, as done
in prior studies [41]. We found that 61% of the primary
and 77% of the metastatic specimens met our definition
for high expression. While it is unknown whether there is
a threshold level above which XIAP inhibitors might be
more effective as therapeutics, our data show that there is
variability in XIAP expression in melanoma, which
should, at the very least, be assessed when XIAP targeting
therapies are used in clinical trials in melanoma patients.
Extensive research has been done on the structure and
function of XIAP, as reviewed in detail by Schimmer et al
[15]. In addition to caspase inhibition, XIAP has a role in
activation of the JNK pathway, with resultant MAP kinase
pathway activation, leading to NF-κB activation [54].
XIAP also activates NF-κB by promoting its nuclear trans-
location [55]. XIAP mediates cell cycle arrest, via regula-
tion of cyclins and cyclin-dependent kinase inhibitors
(CDKIs), and is involved in receptor-mediated signaling
[56].
Targeting XIAP to sensitize cancer cells to chemotherapy is
supported by a number of studies showing that over-
expression of XIAP in cell lines confers chemotherapy
resistance, and that down-regulation of XIAP results in
activation of both the mitochondrial and death receptor
pathways and sensitization to chemotherapy [17,19,57-
59]. Targeting XIAP is unlikely to result in significant tox-
icity as XIAP knock-out mice exhibit normal organ func-
tion [60]. Although clinical toxicity data using the XIAP
targeting drug AEG 35156 are pending, we believe that the
approach of targeting XIAP in order to sensitize
melanoma cells to chemotherapy is worthy of further
investigation.
Phenoxodiol is an isoflavone derivative that has been
shown to cause proteasomal degradation of XIAP, and
reverse chemoresistance in ovarian cancer cells [19]. The
precise target and mechanism of action of Phenoxodiol
remain unknown, and XIAP degradation might be a
downstream effect of Phenoxodiol, rather than a direct
effect of the drug. In ovarian cancer we showed that both
knock down of XIAP by RNA interference and pretreat-
ment with Phenoxodiol result in similar sensitization to
chemotherapy [17]. In this study we demonstrated that
Phenoxodiol treatment of melanoma cells also caused
XIAP degradation, cleavage of pro-caspase-2, and activa-
tion of caspases -3, -8 and -9 in Carboplatin resistant
melanoma cell lines. The pro-apoptotic effect of Phenox-
odiol on melanoma cells potentiated the cytotoxic effects
of Carboplatin, and reduced the IC50 of Carboplatin. We
showed that in our Carboplatin resistant cells, caspase-3
(the main effector caspase) was not activated by Carbopl-
atin alone, yet pre-treatment of YUMAC cells with Phe-
noxodiol for 2 or 4 hours resulted in decreased levels of
XIAP, sensitization to Carboplatin, and remarkable activa-
tion of caspase-3. We note that in the YUSAC2 cells there
was much less XIAP degradation and no meaningful sen-
sitization to Carboplatin. These results confirm previous
studies by our group and others suggesting that intracellu-
lar inhibitors of caspases, such as XIAP, play a major role
in drug-induced apoptosis [17,19,58], and by triggering
caspase activation, Phenoxodiol enhances the cytotoxic
effect of chemotherapy. Although the molecular differ-
ences between these two cell lines have yet to be deter-
mined, these results elucidate potential new targets for
chemoresistance. We are presently screening additional
potential target(s) mediating this resistance.Journal of Translational Medicine 2007, 5:6 http://www.translational-medicine.com/content/5/1/6
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Single agent Carboplatin is not commonly used for
melanoma, whereas Cisplatin is widely used. The chemi-
cal structure of these drugs is very similar, and in most
(but not all) diseases these drugs have demonstrated
equal efficacy. Carboplatin has been used as a singe agent
in Phase II studies for metastatic melanoma, with
response rates of 11–16% [61,62]. Use of single agent Cis-
platin in Phase II trials has resulted in response rates of
10–16% [7,63]. While these two platinum compounds
have not been compared head-to-head for melanoma, the
toxicity associated with Cisplatin often prohibits its use in
patients, and further development of sensitizers to Carbo-
platin is a logical approach. Phenoxodiol has been
assessed in Phase I studies, and is extremely well tolerated
in both the oral and the intravenous forms [19,31,64]. In
our in vitro studies we used a concentration of 10 µg/ml of
Phenoxodiol in order to sensitize cells to Carboplatin. In
clinical trials with oral Phenoxodiol given at a dose of 50
mg/kg, the serum concentration was in the order of 250
µM after 30 minutes of administration [19]. Thus the dose
used in this study (10 µg/ml = 41.62 µM) is readily attain-
able in vivo, and is likely to be well tolerated. Of the three
cell lines we assessed for sensitization to Carboplatin, one
remained resistant after Phenoxodiol pre-treatment. Stud-
ies are underway in our laboratory to assess additional
isoflavone analogues as chemotherapy sensitizers, using a
larger panel of cell lines. However, in select patients
whose tumors demonstrate XIAP degradation with Phe-
noxodiol treatment, use of Phenoxodiol as a chemother-
apy sensitizer is a reasonable approach that warrants
further investigation. These clinical trials should incorpo-
rate assessment of XIAP degradation in short term cultures
after treatment with Phenoxodiol as a biomarker of
response to this combination of therapy. This is currently
being assessed in platinum resistant ovarian cancer
patients treated with Phenoxodiol and Cisplatin.
In summary, our studies show that XIAP is up-regulated in
melanoma specimens compared to nevi, and expression
of XIAP is higher in metastatic than in primary melano-
mas. This is the first study of XIAP expression in a large
cohort of melanoma specimens. Furthermore, we demon-
strate that Phenoxodiol sensitization to Carboplatin in
melanoma is associated with XIAP degradation, although
the precise target of Phenoxodiol is still being studied in
our laboratory. Further studies are needed to determine
whether isoflavone analogues and direct XIAP targeting
therapies can be used as chemotherapy sensitizers in
melanoma patients, and whether XIAP expression levels
are associated with response to therapy.
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